FDA Approves Effervescent Tablet for Treating Osteoporosis–BINOSTO

For those who have trouble swallowing pills a new delivery system for taking a medication to increase bone mass. It won’t be available until sometime in the 3rd quarter. BD

FREIENBACH, Switzerland, March 14, 2012 /PRNewswire/ -- EffRx Pharmaceuticals SA today announced that the U.S. Food and Drug Administration (FDA) has approved BINOSTO™ (alendronate sodium) Effervescent Tablets, previously known as EX101, for the treatment of osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with osteoporosis. EffRx anticipates that BINOSTO™ will be commercially available in the United States in the third quarter of 2012.

Christer Rosen, Chairman & CEO of EffRx states: "We are very pleased to receive this approval from the FDA. BINOSTO™is a breakthrough innovation for the treatment of osteoporosis, offering those patients who have difficulty with tablets the proven fracture risk reduction of alendronate in a pleasant tasting and easy-to-swallow buffered solution."